PDCD1 and lung carcinoma: Anti-PD-1 or anti-PD-L1 antibodies have been authorized for a number of malignancies, such as Hodgkin lymphoma, renal cell carcinoma, and lung cancer, and are currently being studied for almost all forms of cancer.